News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
767,551 Results
Type
Article (50943)
Company Profile (346)
Press Release (716249)
Multimedia
Podcasts (121)
Webinars (23)
Section
Business (213826)
Career Advice (2193)
Deals (36853)
Drug Delivery (131)
Drug Development (83603)
Employer Resources (178)
FDA (17258)
Job Trends (15854)
News (361633)
Policy (35352)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2867)
Academic (2)
Accelerated approval (33)
Adcomms (28)
Allergies (149)
Alliances (52465)
ALS (172)
Alzheimer's disease (1740)
Antibody-drug conjugate (ADC) (327)
Approvals (17508)
Artificial intelligence (568)
Autoimmune disease (163)
Automation (39)
Bankruptcy (370)
Best Places to Work (12310)
BIOSECURE Act (21)
Biosimilars (200)
Biotechnology (209)
Bladder cancer (157)
Brain cancer (59)
Breast cancer (655)
Cancer (4940)
Cardiovascular disease (417)
Career advice (1861)
Career pathing (38)
CAR-T (292)
CDC (57)
Celiac Disease (2)
Cell therapy (769)
Cervical cancer (37)
Clinical research (71213)
Collaboration (1809)
Company closure (4)
Compensation (1171)
Complete response letters (61)
COVID-19 (2915)
CRISPR (101)
C-suite (896)
Cystic fibrosis (150)
Data (6331)
Decentralized trials (2)
Denatured (42)
Depression (144)
Diabetes (520)
Diagnostics (7105)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (268)
Drug pricing (208)
Drug shortages (29)
Duchenne muscular dystrophy (240)
Earnings (92346)
Editorial (64)
Employer branding (22)
Employer resources (156)
Events (126797)
Executive appointments (1036)
FDA (20479)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1556)
Gene editing (214)
Generative AI (53)
Gene therapy (629)
GLP-1 (1034)
Government (5257)
Grass and pollen (7)
Guidances (386)
Healthcare (20462)
HIV (63)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (265)
Immuno-oncology (60)
Indications (113)
Infectious disease (3210)
Inflammatory bowel disease (198)
Inflation Reduction Act (17)
Influenza (125)
Intellectual property (255)
Interviews (348)
IPO (17093)
IRA (54)
Job creations (3905)
Job search strategy (1549)
JPM (67)
Kidney cancer (16)
Labor market (88)
Layoffs (575)
Leadership (34)
Legal (8545)
Liver cancer (96)
Longevity (15)
Lung cancer (659)
Lymphoma (380)
Machine learning (43)
Management (61)
Manufacturing (826)
MASH (172)
Medical device (14640)
Medtech (14697)
Mergers & acquisitions (20859)
Metabolic disorders (1332)
Multiple sclerosis (167)
NASH (17)
Neurodegenerative disease (337)
Neuropsychiatric disorders (94)
Neuroscience (3020)
Neurotech (1)
NextGen: Class of 2026 (7178)
Non-profit (4969)
Now hiring (67)
Obesity (635)
Opinion (295)
Ovarian cancer (168)
Pain (209)
Pancreatic cancer (236)
Parkinson's disease (291)
Partnered (35)
Patents (509)
Patient recruitment (505)
Peanut (58)
People (62002)
Pharmaceutical (74)
Pharmacy benefit managers (32)
Phase 1 (22271)
Phase 2 (31187)
Phase 3 (23275)
Pipeline (5429)
Policy (314)
Postmarket research (2766)
Preclinical (9453)
Press Release (71)
Prostate cancer (247)
Psychedelics (53)
Radiopharmaceuticals (294)
Rare diseases (884)
Real estate (6344)
Recruiting (71)
Regulatory (26161)
Reports (54)
Research institute (2629)
Resumes & cover letters (376)
Rett syndrome (27)
RNA editing (18)
RSV (83)
Schizophrenia (152)
Series A (259)
Series B (202)
Service/supplier (16)
Sickle cell disease (104)
Special edition (26)
Spinal muscular atrophy (164)
Sponsored (47)
Startups (3859)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (89)
The Weekly (77)
Vaccines (1118)
Venture capital (95)
Weight loss (413)
Women's health (96)
Worklife (19)
Date
Today (133)
Last 7 days (579)
Last 30 days (2263)
Last 365 days (31140)
2026 (3779)
2025 (31466)
2024 (36597)
2023 (41560)
2022 (52848)
2021 (57592)
2020 (56611)
2019 (49858)
2018 (37774)
2017 (33906)
2016 (34016)
2015 (40083)
2014 (33719)
2013 (28753)
2012 (30978)
2011 (31591)
2010 (29797)
Location
Africa (872)
Alabama (89)
Alaska (7)
Arizona (328)
Arkansas (14)
Asia (42492)
Australia (7025)
California (11592)
Canada (3345)
China (1140)
Colorado (492)
Connecticut (508)
Delaware (346)
Europe (93716)
Florida (1720)
Georgia (376)
Hawaii (4)
Idaho (67)
Illinois (923)
India (68)
Indiana (541)
Iowa (23)
Japan (442)
Kansas (131)
Kentucky (41)
Louisiana (28)
Maine (83)
Maryland (1439)
Massachusetts (8397)
Michigan (356)
Minnesota (665)
Mississippi (6)
Missouri (141)
Montana (34)
Nebraska (28)
Nevada (127)
New Hampshire (84)
New Jersey (3124)
New Mexico (30)
New York (3069)
North Carolina (1562)
North Dakota (9)
Northern California (5630)
Ohio (355)
Oklahoma (23)
Oregon (43)
Pennsylvania (2320)
Puerto Rico (24)
Rhode Island (50)
South America (1249)
South Carolina (68)
South Dakota (1)
Southern California (4525)
Tennessee (177)
Texas (1809)
United States (41528)
Utah (349)
Vermont (1)
Virginia (279)
Washington D.C. (85)
Washington State (953)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
767,551 Results for "vigil health solutions inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial
Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts say the outcome is unsurprising and shouldn’t affect the deal.
June 4, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
August 6, 2025
·
5 min read
Press Releases
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
January 15, 2026
·
8 min read
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
February 17, 2026
·
3 min read
Press Releases
Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call
January 13, 2026
·
1 min read
Press Releases
Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call
January 27, 2026
·
2 min read
Press Releases
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 29, 2026
·
1 min read
Press Releases
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
May 22, 2025
·
9 min read
Press Releases
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Australia’s Department of Health has issued import permits for Optimi’s MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme
January 26, 2026
·
1 min read
1 of 76,756
Next
